Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Protein Expression and Purification|April 7, 2021
Expression and purification of a novel single-chain diabody (scDb-hERG1/β1) from Pichia pastoris transformantsClaudia Duranti, Elena Lastraioli, Jessica Iorio, et al.
Cancers|August 27, 2021
A Transcriptomic Approach Reveals Selective Ribosomal Remodelling in the Tumour Versus the Stromal Compartment of Metastatic Colorectal CancerElena Lastraioli, Federico Alessandro Ruffinatti, Francesco Di Costanzo, et al.
Anti-Cancer Drugs|September 5, 2020
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case reportElena Lastraioli, Daniele Lavacchi, Valeria Emma Palmieri, et al.
International Journal of Molecular Sciences|July 9, 2022
The Transcriptional Landscape of <i>BRAF</i> Wild Type Metastatic Melanoma: A Pilot StudyElena Lastraioli, Federico Alessandro Ruffinatti, Giacomo Bagni, et al.
Frontiers in Endocrinology|November 8, 2017
Circulating Endothelial Progenitor Cells in Type 1 Diabetic Patients: Relation with Patients' Age and Disease DurationAdolfo Arcangeli, Elena Lastraioli, Barbara Piccini, et al.
Scientific Reports|April 24, 2021
Transgenic mice overexpressing the LH receptor in the female reproductive system spontaneously develop endometrial tumour massesTiziano Lottini, Jessica Iorio, Elena Lastraioli, et al.
Autoimmunity Reviews|March 5, 2025
Epigenetics in autoimmune diseases: Unraveling the hidden regulators of immune dysregulationGiacomo Bagni, Edoardo Biancalana, Emanuele Chiara, et al.
Journal of Translational Autoimmunity|June 18, 2025
Epigenetic regulation of thrombo-inflammation in Behçet and antiphospholipid syndromeAlessandra Bettiol, Giacomo Bagni, Francesca Di Patti, et al.
Gynecologic Oncology|October 3, 2008
hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancerIvo Noci, Serena Pillozzi, Elena Lastraioli, et al.
Oncotargets and Therapy|October 30, 2016
hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapyLeonardo Muratori, Giulia Petroni, Lorenzo Antonuzzo, et al.
Pageof 5